Yuri Tolkach1, Eva-Maria Niehoff2, Anna Franziska Stahl2, Chenming Zhao2, Glen Kristiansen3, Stefan C Müller2, Jörg Ellinger4,5. 1. Institute of Pathology, University Hospital Bonn, Sigmund-Freud-Strasse 25, 53105, Bonn, Germany. yuri.tolkach@ukbonn.de. 2. Department of Urology, University Hospital Bonn, Bonn, Germany. 3. Institute of Pathology, University Hospital Bonn, Sigmund-Freud-Strasse 25, 53105, Bonn, Germany. 4. Department of Urology, University Hospital Bonn, Bonn, Germany. joerg.ellinger@ukbonn.de. 5. Klinik und Poliklinik für Urologie und Kinderurologie, Universitätsklinikum Bonn, Sigmund-Freud-Strasse 25, 53105, Bonn, Germany. joerg.ellinger@ukbonn.de.
Abstract
OBJECTIVE: To study the expression of YRNAs (Ro-associated Y), a novel class of non-coding RNAs, in prostate cancer (PCA) patients. METHODS: The expression of all four YRNAs (RNY1, RNY3, RNY4, RNY5) was determined in archival PCA (prostate adenocarcinoma, n = 56), normal (n = 36) and benign prostatic hyperplasia (BPH; n = 28) tissues using quantitative real-time PCR. Associations with clinicopathological parameters and prognostic role for biochemical recurrence-free survival were analysed. RESULTS: All YRNAs were significantly downregulated in PCA tissue compared to normal tissue (all YRNAs) and to BPH tissue (RNY4 and RNY5; RNY1 and RNY3 as trend). Among tumor ISUP grade groups, the most prominent differences in the expression were evident between groups 1 and 2 (RNY1, RNY3 und RNY4; all p < 0.05). Discrimination ability for normal/BPH tissue versus tumor tissue in ROC analysis (area under curve) was ranging from 0.658 (RNY1) to 0.739 (RNY4). Higher RNY5 expression was associated with poor prognosis (biochemical recurrence-free survival). CONCLUSION: The expression of YRNAs is altered in PCA and associated with poor prognosis (RNY5). Possible diagnostic role of YRNAs in prostate cancer should be investigated in further studies.
OBJECTIVE: To study the expression of YRNAs (Ro-associated Y), a novel class of non-coding RNAs, in prostate cancer (PCA) patients. METHODS: The expression of all four YRNAs (RNY1, RNY3, RNY4, RNY5) was determined in archival PCA (prostate adenocarcinoma, n = 56), normal (n = 36) and benign prostatic hyperplasia (BPH; n = 28) tissues using quantitative real-time PCR. Associations with clinicopathological parameters and prognostic role for biochemical recurrence-free survival were analysed. RESULTS: All YRNAs were significantly downregulated in PCA tissue compared to normal tissue (all YRNAs) and to BPH tissue (RNY4 and RNY5; RNY1 and RNY3 as trend). Among tumor ISUP grade groups, the most prominent differences in the expression were evident between groups 1 and 2 (RNY1, RNY3 und RNY4; all p < 0.05). Discrimination ability for normal/BPH tissue versus tumor tissue in ROC analysis (area under curve) was ranging from 0.658 (RNY1) to 0.739 (RNY4). Higher RNY5 expression was associated with poor prognosis (biochemical recurrence-free survival). CONCLUSION: The expression of YRNAs is altered in PCA and associated with poor prognosis (RNY5). Possible diagnostic role of YRNAs in prostate cancer should be investigated in further studies.
Authors: Timothy J Wilt; Karen M Jones; Michael J Barry; Gerald L Andriole; Daniel Culkin; Thomas Wheeler; William J Aronson; Michael K Brawer Journal: N Engl J Med Date: 2017-07-13 Impact factor: 91.245
Authors: Berta Victoria Martinez; Joseph M Dhahbi; Yury O Nunez Lopez; Katarzyna Lamperska; Paweł Golusinski; Lukasz Luczewski; Tomasz Kolenda; Hani Atamna; Stephen R Spindler; Wojciech Golusinski; Michal M Masternak Journal: Oncotarget Date: 2015-08-07
Authors: Kacper Guglas; Tomasz Kolenda; Maciej Stasiak; Magda Kopczyńska; Anna Teresiak; Matthew Ibbs; Renata Bliźniak; Katarzyna Lamperska Journal: Cells Date: 2020-05-21 Impact factor: 6.600
Authors: Joseph Dhahbi; Yury O Nunez Lopez; Augusto Schneider; Berta Victoria; Tatiana Saccon; Krish Bharat; Thaddeus McClatchey; Hani Atamna; Wojciech Scierski; Pawel Golusinski; Wojciech Golusinski; Michal M Masternak Journal: Front Oncol Date: 2019-09-26 Impact factor: 6.244
Authors: Melinda Szilágyi; Ondrej Pös; Éva Márton; Gergely Buglyó; Beáta Soltész; Judit Keserű; András Penyige; Tomas Szemes; Bálint Nagy Journal: Int J Mol Sci Date: 2020-09-17 Impact factor: 5.923